Skip to main content

yartemlea

Generic: narsoplimab-wuug·Code: narsoplimab-wuug

yartemlea: sourced relationships with 1 company · 1 FDA decision.

yartemlea evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect yartemlea to OMER; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could yartemlea → OMER affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
OMEROS CORP (OMER)
developer · Reported 2026-03-31 · Current development: unknownSource
hematopoietic stem cell transplant-associated thrombotic mic…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )(OMER)FDA ↗
BLA761152Type 1 - New Molecular EntityOrphan DrugPriorityInjection

Frequently asked questions

Which companies have sourced relationships with yartemlea?

yartemlea has dated SEC/FDA relationship records for OMEROS CORP.

What is yartemlea's latest FDA decision?

The most recent tracked FDA decision for yartemlea is Approval for 1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 ), dated December 23, 2025.